

## Quality ID #383 (CBE 1879): Adherence to Antipsychotic Medications For Individuals with Schizophrenia

### 2026 COLLECTION TYPE:

MERIT-BASED INCENTIVE PAYMENT SYSTEM (MIPS) CLINICAL QUALITY MEASURE (COM)

### MEASURE TYPE:

Intermediate Outcome – High Priority

### DESCRIPTION:

Percentage of individuals at least 18 years of age as of the beginning of the performance period with schizophrenia or schizoaffective disorder who had at least two prescriptions filled for any antipsychotic medication and who had a Proportion of Days Covered (PDC) of at least 0.8 for antipsychotic medications during the performance period.

### INSTRUCTIONS:

#### **Reporting Frequency:**

This measure is to be submitted a minimum of **once per performance period** for denominator eligible cases as defined in the denominator criteria.

#### **Intent and Clinician Applicability:**

This measure is intended to reflect the quality of services provided for patients with a diagnosis of schizophrenia or schizoaffective disorder. This measure may be submitted by Merit-based Incentive Payment System (MIPS) eligible clinicians who perform the quality actions as defined by the numerator based on the services provided and the measure-specific denominator coding.

#### **Measure Strata and Performance Rates:**

This measure contains one strata defined by a single submission criteria.

This measure produces a single performance rate.

#### **Implementation Considerations:**

For the purposes of MIPS implementation, this patient-process measure is submitted a minimum of once per patient for the performance period. The most advantageous quality data code will be used if the measure is submitted more than once.

#### **Telehealth:**

**TELEHEALTH ELIGIBLE:** This measure **is appropriate for and applicable to the telehealth setting**. Patient encounters conducted via telehealth using encounter code(s) found in the denominator encounter criteria are allowed for this measure. Therefore, if the patient meets all denominator criteria for a telehealth encounter, it would be appropriate to include them in the denominator eligible patient population. Telehealth eligibility is at the measure level for inclusion within the denominator eligible patient population and based on the measure specification definitions which are independent of changes to coding and/or billing practices.

#### **Measure Submission:**

The quality data codes listed do not need to be submitted by MIPS eligible clinicians, groups, or third party intermediaries that utilize this collection type for submissions; however, these codes may be submitted for those third party intermediaries that utilize Medicare Part B claims data. The coding provided to identify the measure criteria: Denominator or Numerator, may be an example of coding that could be used to identify patients that meet the intent of this clinical topic. When implementing this measure, please refer to the 'Reference Coding' section to determine if other codes or code languages that meet the intent of the criteria may also be used within the medical record to identify and/or assess patients. For more information regarding Application Programming Interface (API), please refer to the Quality Payment Program (QPP) website.

### DENOMINATOR:

Individuals at least 18 years of age as of the beginning of the performance period with schizophrenia or schizoaffective disorder and at least two prescriptions filled for antipsychotic medications during the performance period.

**DENOMINATOR NOTE:**

\*Signifies that this CPT Category I or HCPCS code is a non-covered service under the Medicare Part B Physician Fee Schedule (PFS). These non-covered services should be counted in the denominator population for MIPS QOMs.

<b>ORAL ANTIPSYCHOTIC MEDICATIONS:</b>		<b>LONG-ACTING INJECTABLE ANTIPSYCHOTIC MEDICATIONS:</b>
<b>NOTE:</b> The following are the oral antipsychotic medications for the denominator. The route of administration includes all oral formulations of the medications listed below.		<b>NOTE:</b> The following are the long-acting (depot) injectable antipsychotic medications for the denominator. The route of administration includes all injectable and intramuscular formulations of the medications listed below.
<b>ANTIPSYCHOTIC MEDICATIONS:</b>	<b>ANTIPSYCHOTIC COMBINATIONS:</b>	<b>ANTIPSYCHOTIC MEDICATIONS:</b>
aripiprazole	perphenazine-amitriptyline	aripiprazole
asenapine		aripiprazole lauroxil (Aristada)
brexiprazole		fluphenazine decanoate
cariprazine		haloperidol decanoate
aripiprazole		olanzapine pamoate
chlorpromazine		paliperidone palmitate
clozapine		risperidone microspheres
fluphenazine		
haloperidol		
iloperidone		
loxapine		
lumateperone		
lurasidone		
molindone		
olanzapine		
paliperidone		
perphenazine		
prochlorperazine		
quetiapine		
quetiapine fumarate (Seroquel)		
risperidone		
thioridazine		
thiothixene		
trifluoperazine		
ziprasidone		

**Denominator Criteria (Eligible Cases):**

Patients aged ≥ 18 years at the beginning of the performance period

**AND**

Diagnosis for schizophrenia or schizoaffective disorder during at least one encounter in an acute inpatient setting (ICD-10-CM): F20.0, F20.1, F20.2, F20.3, F20.5, F20.81, F20.89, F20.9, F25.0, F25.1, F25.8, F25.9

**AND**

Acute Inpatient Setting (CPT): 90791, 90792, 90832, 90834, 90837, 90839, 90845, 90847, 90849, 90853, 90867, 90868, 90869, 90870, 90875\*, 90876\*, 99221, 99222, 99223, 99231, 99232, 99233, 99238, 99239, 99252\*, 99253\*, 99254\*, 99255\*, 99291

**WITH**

Place of Service (POS): 21, 51

**OR**

Diagnosis for schizophrenia or schizoaffective disorder during at least two encounters in an outpatient, emergency department, or non-acute inpatient setting (ICD-10-CM): F20.0, F20.1, F20.2, F20.3, F20.5, F20.81, F20.89, F20.9, F25.0, F25.1, F25.8, F25.9

**AND**

Outpatient, Emergency Department, or Non-Acute Inpatient Setting (CPT or HCPCS): 90791, 90792, 90832, 90834, 90837, 90839, 90845, 90847, 90849, 90853, 90867, 90868, 90869, 90870, 90875\*, 90876\*, 90880, 98000, 98001, 98002, 98003, 98004, 98005, 98006, 98007, 98008, 98009, 98010, 98011, 98012, 98013, 98014, 98015, 98016, 98960, 98961, 98962, 99078, 99202, 99203, 99204, 99205, 99211, 99212, 99213, 99214, 99215, 99238, 99239, 99242\*, 99243\*, 99244\*, 99245\*, 99252\*, 99253\*, 99254\*, 99255\*, 99281, 99282, 99283, 99284, 99285\*, 99291, 99304, 99305, 99306, 99307, 99308, 99309, 99310, 99315, 99316, 99341, 99342, 99344, 99345, 99347, 99348, 99349, 99350, 99385\*, 99386\*, 99387\*, 99395\*, 99396\*, 99397\*, 99401\*, 99402\*, 99403\*, 99404\*, 99411\*, 99412\*, 99424, 99426, 99429\*, 99490, 99491, 99510, G0155\*, G0176\*, G0177\*, G0409, G0410\*, G0411\*, G0463\*, G0469\*, G0470\*, H0002\*, H0004\*, H0017, H0018, H0019, H0031\*, H0034\*, H0035\*, H0036\*, H0037\*, H0039\*, H0040\*, H2000\*, H2001\*, H2010\*, H2011\*, H2012\*, H2013\*, H2014\*, H2015\*, H2016\*, H2017\*, H2018\*, H2019\*, H2020\*, S0201\*, S9480\*, S9484\*, S9485\*, T1015\*, T2048

**WITH**

Outpatient Place of Service (POS): 02, 03, 04, 05, 07, 09, 10, 11, 12, 13, 14, 15, 16, 17, 19, 20, 22, 24, 33, 49, 50, 52, 53, 54, 57, 58, 62, 65, 71, 72

**OR**

Emergency Department Place of Service (POS): 23

**OR**

Non-Acute Inpatient Place of Service (POS): 31, 32, 55, 56, 61

**AND**

Filled at least two prescriptions during the performance period for any combination of the qualifying oral antipsychotic medications listed under “Denominator Note” or the long-acting injectable antipsychotic medications listed under “Denominator Note”: M1380

**AND NOT**

**DENOMINATOR EXCLUSION:**

Patient ever had a diagnosis of dementia: M1452

**Reference Coding:**

Denominator Exclusion for Dementia [M1452] is defined by the following coding **only**:

E75.00, E75.01, E75.02, E75.09, E75.10, E75.11, E75.19, E75.244, E75.4, F01.50, F01.51, F01.511, F01.518, F01.52, F01.53, F01.54, F01.A0, F01.A11, F01.A18, F01.A2, F01.A3, F01.A4, F01.B0, F01.B11, F01.B18, F01.B2, F01.B3, F01.B4, F01.C0, F01.C11, F01.C18, F01.C2, F01.C3, F01.C4, F02.80, F02.81, F02.811, F02.818, F02.82, F02.83, F02.84, F02.A0, F02.A11, F02.A18, F02.A2, F02.A3, F02.A4, F02.B0, F02.B11, F02.B18, F02.B2, F02.B3, F02.B4, F02.C0, F02.C11, F02.C18, F02.C2, F02.C3, F02.C4, F03.90, F03.91, F03.911, F03.918, F03.92, F03.93, F03.94, F03.A0, F03.A11, F03.A18, F03.A2, F03.A3, F03.A4, F03.B0, F03.B11, F03.B18, F03.B2, F03.B3, F03.B4, F03.C0, F03.C11, F03.C18, F03.C2, F03.C3, F03.C4, F05, F10.27, F11.122, F13.27, F13.97, F18.17, F18.27, F18.97, F19.17, F19.27, F19.97, G30.0, G30.1, G30.8, G30.9, G31.09, G31.83

**NUMERATOR:**

Individuals in the denominator who have a Proportion of Days Covered (PDC) of at least 0.8 for antipsychotic medications.

**NUMERATOR NOTE:**

The PDC is calculated as follows:

**PDC NUMERATOR:**

The PDC numerator is the sum of the days covered by the days' supply of all antipsychotic prescriptions. The period covered by the PDC starts on the day within the performance period when the first prescription is filled (i.e., the index date) and lasts through the end of the performance period, or death, whichever comes first. For prescriptions with a days' supply that extends beyond the end of the performance period, count only the days for which the drug was available to the individual during the performance period. If there are prescriptions for the same drug (generic name) on the same date of service, keep the prescription with the largest days' supply. If prescriptions for the same drug (generic name) overlap, then adjust the prescription start date to be the day after the previous fill has ended.

**PDC DENOMINATOR:**

*The period covered by the PDC starts on the day within the performance period when the first prescription is filled (i.e., the index date) and lasts through the end of the performance period, or death, whichever comes first.*

**Numerator Options:****Performance Met:**

Individual had a PDC of 0.8 or greater (G9512)

**OR**

**Performance Not Met:**

Individual did not have a PDC of 0.8 or greater (G9513)

**RATIONALE:**

A large body of evidence has shown that antipsychotic medications (APMs) are effective in treating acute psychotic exacerbations of schizophrenia and in reducing the likelihood of relapse. Guidelines from the National Institute for Clinical Excellence (NICE) and the American Psychiatric Association (APA) emphasize the importance of treatment adherence and uninterrupted antipsychotic regimens to prevent symptoms and relapse [1,2]. However, some studies estimate that the rate of adherence to APMs among patients diagnosed with schizophrenia is about 50 percent, much lower than the 80 percent threshold often used to define adherence [3]. Factors associated with poor medication adherence include greater symptom severity, a more frequent dosing regimen, poor insight, and a more negative attitude towards drugs [4,5]. Some studies have also identified Latino and African American ethnicity, lack of housing, and co-occurring behavioral health and substance use conditions as predictors of increased nonadherence to antipsychotic medications [6]. This measure describes the degree of compliance or non-compliance with recommendations related to medication adherence among patients with schizophrenia and, in doing so, has the potential to improve management of schizophrenia. This measure addresses a Healthy People 2030 goal to increase the proportion of adults with serious mental illness who receive treatment [7].

Although the prevalence of schizophrenia in the adult American population is less than 1%, this population has a higher risk of premature mortality than the general population [8]. The estimated average potential life lost is 28.5 years for individuals with schizophrenia compared to the general population [9]. The overall U.S. cost of schizophrenia has been estimated at \$155.7 billion annually with direct health care costs of \$37.7 billion [10]. Antipsychotic medications have proven to be effective in treating this disease. Additionally, adherence to APMs has been associated with lower rates of preventable diabetes hospitalizations and lower rates of emergency department utilization among patients with schizophrenia [11,12,13].

**CLINICAL RECOMMENDATION STATEMENTS:**

The 2014 NICE Guideline on Treatment and Management of Psychosis and Schizophrenia in Adults recommends that “for people with an acute exacerbation or recurrence of psychosis or schizophrenia, offer oral antipsychotic medication in conjunction with psychological interventions (family intervention and individual [cognitive behavioral therapy])”. The guideline also recommends to “consider offering depot /long-acting injectable antipsychotic medication to people with psychosis or schizophrenia who would prefer such treatment after an acute episode [or] where avoiding covert non-adherence (either intentional or unintentional) to antipsychotic medication is a clinical priority within the treatment plan”. These recommendations are found on pages 381 and 382 of the 2014 NICE Guideline under the Clinical Practice Recommendations, Treatment of Acute Episode and Promoting Recovery sections, respectively [2].

The American Psychological Association (APA) updated its guidelines for treating patients diagnosed with schizophrenia in December 2019. The following statements pertaining to the use of antipsychotic medications were included in the 2019 guidelines with a grade of 1A, indicating that there was high quality evidence to support them:

The APA recommends that patients with schizophrenia be treated with an antipsychotic medication and monitored for effectiveness and side effects.

The APA recommends that patients with schizophrenia whose symptoms have improved with an antipsychotic medication continue to be treated with an antipsychotic medication [1].

**REFERENCES:**

1. American Psychiatric Association. (2020). The American Psychiatric Association Practice Guideline for the Treatment of Patients with Schizophrenia (Third Edition). Retrieved from <https://psychiatryonline.org/doi/book/10.1176/appi.books.9780890424841>
2. National Collaborating Centre for Mental Health. (2014). Psychosis and schizophrenia in adults. Retrieved from <https://www.nice.org.uk/guidance/cg178/evidence/full-guideline-pdf-490503565>
3. Sendt, K. V., Tracy, D. K., & Bhattacharyya, S. (2015). A systematic review of factors influencing adherence to antipsychotic

medication in schizophrenia-spectrum disorders. *Psychiatry Research*, 225(1–2), 14–30.

<https://doi.org/10.1016/j.psychres.2014.11.002>

4. Yaegashi, H., Kirino, S., Remington, G., Misawa, F., & Takeuchi, H. (2020). Adherence to Oral Antipsychotics Measured by Electronic Adherence Monitoring in Schizophrenia: A Systematic Review and Meta-analysis. *CNS Drugs*, 34(6), 579–598. <https://doi.org/10.1007/s40263-020-00713-9>
5. Kim, J., Ozzoude, M., Nakajima, S., Shah, P., Caravaggio, F., Iwata, Y., . . . Gerretsen, P. (2020). Insight and medication adherence in schizophrenia: An analysis of the CATIE trial. *Neuropharmacology*, 168, 107634. <https://doi.org/10.1016/j.neuropharm.2019.05.011>
6. Horvitz-Lennon, M., Volya, R., Donohue, J. M., Lave, J. R., Stein, B. D., & Normand, S. L. T. (2014). Disparities in Quality of Care among Publicly Insured Adults with Schizophrenia in Four Large U.S. States, 2002–2008. *Health Services Research*, 49(4), 1121–1144. <https://doi.org/10.1111/1475-6773.12162>
7. Office of Disease Prevention and Health Promotion. (2020). Mental Health and Mental Disorders - Healthy People 2030. Retrieved from <https://health.gov/healthypeople/objectives-and-data/browse-objectives/mental-health-and-mental-disorders>
8. Kessler, R. C., Birnbaum, H., Demler, O., Falloon, I. R., Gagnon, E., Guyer, M., . . . Wu, E. Q. (2005). The Prevalence and Correlates of Nonaffective Psychosis in the National Comorbidity Survey Replication (NCS-R). *Biological Psychiatry*, 58(8), 668–676. <https://doi.org/10.1016/j.biopsych.2005.04.034>
9. Olsson, M., Gerhard, T., & Huang, C. (2015). Premature Mortality Among Adults With Schizophrenia in the United States. *JAMA Psychiatry*, 72(12), 1172–1181. [doi:10.1001/jamapsychiatry.2015.1737](https://doi.org/10.1001/jamapsychiatry.2015.1737)
10. Cloutier, M., Aigbogun, M. S., Guerin, A., Nitulescu, R., Ramanakumar, . . . Wu, E. (2016). The Economic Burden of Schizophrenia in the United States in 2013. *The Journal of clinical psychiatry*, 77(6), 764–771. <https://doi.org/10.4088/JCP.15m10278>
11. Egglefield, K., Cogan, L., Leckman-Westin, E., & Finnerty, M. (2020). Antipsychotic medication adherence and diabetes-related hospitalizations among Medicaid recipients with diabetes and schizophrenia. *Psychiatric Services*, 71(3), 236–242. [doi:10.1176/appi.ps.201800505](https://doi.org/10.1176/appi.ps.201800505)
12. Hardy, M., Jackson, C., & Byrne, J. (2018). Antipsychotic adherence and emergency department utilization among patients with schizophrenia. *Schizophrenia Research*, 201, 347–351. [doi:10.1016/j.schres.2018.06.006](https://doi.org/10.1016/j.schres.2018.06.006)
13. MacEwan, J. P., Silverstein, A. R., Shafrin, J., Lakdawalla, D. N., Hatch, A., & Forma, F. M. (2018). Medication adherence patterns among patients with multiple serious mental and physical illnesses. *Advances in Therapy*, 35(5), 671–685. [doi:10.1007/s12325-018-0700-6](https://doi.org/10.1007/s12325-018-0700-6)

## **COPYRIGHT:**

**THE MEASURES AND SPECIFICATIONS ARE PROVIDED “AS IS” WITHOUT WARRANTY OF ANY KIND.**

©

This measure is owned and stewarded by the Centers for Medicare & Medicaid Services (CMS). CMS contracted (Contract # 75FCMC18D0027/ Task Order # 75FCMC24F0144) with the American Institutes for Research (AIR) to develop this measure. AIR is not responsible for any use of the Measure. AIR makes no representations, warranties, or endorsement about the quality of any organization or physician that uses or reports performance measures and AIR has no liability to anyone who relies on such measures or specifications. This measure is in the public domain.


Limited proprietary coding is contained in the measure specifications for convenience. Users of the proprietary code sets should obtain all necessary licenses from the owners of these code sets. AIR disclaims all liability for use or accuracy of any third party codes contained in the specifications.


CPT® contained in the measure’s specifications is copyright 2004-2025 American Medical Association. ICD-10 copyright 2025 World Health Organization. All Rights Reserved.

This performance measure is not clinical a guideline, does not establish a standard of medical care, and has not been tested for all potential applications.

**2026 Clinical Quality Measure Flow for Quality ID #383 (CBE 1879):  
Adherence to Antipsychotic Medications for Individuals with Schizophrenia**

*Disclaimer: Refer to the measure specification for specific coding and instructions to submit this measure.*





#### SAMPLE CALCULATIONS

##### Data Completeness=

$$\frac{\text{Performance Met (a=40 patients)} + \text{Performance Not Met (c=30 patients)}}{\text{Eligible Population / Denominator (d=80 patients)}} = \frac{70 \text{ patients}}{80 \text{ patients}} = 87.50\%$$

##### Performance Rate=

$$\frac{\text{Performance Met (a=40 patients)}}{\text{Data Completeness Numerator (70 patients)}} = \frac{40 \text{ patients}}{70 \text{ patients}} = 57.14\%$$

\*See the posted measure specification for specific coding and instructions to submit this measure.

NOTE: Submission Frequency: Patient-Process

CPT only copyright 2025 American Medical Association. All rights reserved. The measure diagrams were developed by CMS as a supplemental resource to be used in conjunction with the measure specifications. They should not be used alone or as a substitution for the measure specification.

v10



**2026 Clinical Quality Measure Flow Narrative for Quality ID #383 (CBE 1879):  
Adherence to Antipsychotic Medications for Individuals with Schizophrenia**

*Disclaimer: Refer to the measure specification for specific coding and instructions to submit this measure.*

1. Start with Denominator
2. Check *Patients aged greater than or equal to 18 years at the beginning of the performance period*:
  - a. If *Patients aged greater than or equal to 18 years at the beginning of the performance period* equals No, do not include in *Eligible Population/Denominator*. Stop processing.
  - b. If *Patients aged greater than or equal to 18 years at the beginning of the performance period* equals Yes, proceed to check *Diagnosis for schizophrenia or schizoaffective disorder during at least one encounter in an acute inpatient setting as listed in Denominator\**.
3. Check *Diagnosis for schizophrenia or schizoaffective disorder during at least one encounter in an acute inpatient setting as listed in Denominator\**:
  - a. If *Diagnosis for schizophrenia or schizoaffective disorder during at least one encounter in an acute inpatient setting as listed in Denominator\** equals No, proceed to check *Diagnosis for schizophrenia or schizoaffective disorder during at least two encounters in an outpatient, emergency department, or non-acute inpatient setting as listed in Denominator\**.
  - b. If *Diagnosis for schizophrenia or schizoaffective disorder during at least one encounter in an acute inpatient setting as listed in Denominator\** equals Yes, proceed to check *Filled greater than or equal to 2 prescriptions during the performance period for any combination of the qualifying oral antipsychotic medications listed under "Denominator Note" or the long-acting injectable antipsychotic medications listed under "Denominator Note"*.
4. Check *Diagnosis for schizophrenia or schizoaffective disorder during at least two encounters in an outpatient, emergency department, or non-acute inpatient setting as listed in Denominator\**:
  - a. If *Diagnosis for schizophrenia or schizoaffective disorder during at least two encounters in an outpatient, emergency department, or non-acute inpatient setting as listed in Denominator\** equals No, do not include in *Eligible Population/Denominator*. Stop processing.
  - b. If *Diagnosis for schizophrenia or schizoaffective disorder during at least two encounters in an outpatient, emergency department, or non-acute inpatient setting as listed in Denominator\** equals Yes, proceed to check *Outpatient POS as listed in Denominator\**.
5. Check *Outpatient POS as listed in Denominator\**:
  - a. If *Outpatient POS as listed in Denominator\** equals No, proceed to check *Emergency Department POS*.
  - b. If *Outpatient POS as listed in Denominator\** equals Yes, proceed to check *Filled greater than or equal to 2 prescriptions during the performance period for any combination of the qualifying oral antipsychotic medications listed under "Denominator Note" or the long-acting injectable antipsychotic medications listed under "Denominator Note"*.
6. Check *Emergency Department POS*:
  - a. If *Emergency Department POS* equals No, proceed to check *Non-Acute Inpatient POS as listed in Denominator\**.
  - b. If *Emergency Department POS* equals Yes, proceed to check *Filled greater than or equal to 2 prescriptions during the performance period for any combination of the qualifying oral antipsychotic medications listed under*



*"Denominator Note" or the long-acting injectable antipsychotic medications listed under "Denominator Note" as listed in Denominator\*.*

7. Check *Non-Acute Inpatient POS as listed in Denominator\**:
  - a. If *Non-Acute Inpatient POS as listed in Denominator\** equals No, do not include in *Eligible Population/Denominator*. Stop processing.
  - b. If *Non-Acute Inpatient POS as listed in Denominator\** equals Yes, proceed to check *Filled greater than or equal to 2 prescriptions during the performance period for any combination of the qualifying oral antipsychotic medications listed under "Denominator Note" or the long-acting injectable antipsychotic medications listed under "Denominator Note"*.
8. Check *Filled greater than or equal to 2 prescriptions during the performance period for any combination of the qualifying oral antipsychotic medications listed under "Denominator Note" or the long-acting injectable antipsychotic medications listed under "Denominator Note"*:
  - a. If *Filled greater than or equal to 2 prescriptions during the performance period for any combination of the qualifying oral antipsychotic medications listed under "Denominator Note" or the long-acting injectable antipsychotic medications listed under "Denominator Note"* equals No, do not include in *Eligible Population/Denominator*. Stop processing.
  - b. If *Filled greater than or equal to 2 prescriptions during the performance period for any combination of the qualifying oral antipsychotic medications listed under "Denominator Note" or the long-acting injectable antipsychotic medications listed under "Denominator Note"* equals Yes, proceed to check *Patient ever had a diagnosis of dementia*.
9. Check *Patient ever had a diagnosis of dementia*:
  - a. If *Patient ever had a diagnosis of dementia* equals Yes, do not include in *Eligible Population/Denominator*. Stop processing.
  - b. If *Patient ever had a diagnosis of dementia* equals No, include in *Eligible Population/Denominator*.
10. Denominator Population:
  - Denominator Population is All Eligible Patients in the Denominator. Denominator is represented as Denominator in the Sample Calculation listed at the end of this document. Letter d equals 80 patients in the Sample Calculation.
11. Start Numerator
12. Check *Individual had a PDC of 0.8 or greater*:
  - a. If *Individual had a PDC of 0.8 or greater* equals Yes, include in *Data Completeness Met and Performance Met*.
    - *Data Completeness Met and Performance Met* letter is represented in the Data Completeness and Performance Rate in the Sample Calculation listed at the end of this document. Letter a equals 40 patients in Sample Calculation.
  - b. If *Individual had a PDC of 0.8 or greater* equals No, proceed to check *Individual did not have a PDC of 0.8 or greater*.

13. Check *Individual did not have a PDC of 0.8 or greater*:

a. If *Individual did not have a PDC of 0.8 or greater* equals Yes, include in *Data Completeness Met and Performance Not Met*.

- *Data Completeness Met and Performance Not Met* letter is represented in the Data Completeness in the Sample Calculation listed at the end of this document. Letter c equals 30 patients in the Sample Calculation.

b. If *Individual did not have a PDC of 0.8 or greater* equals No, proceed to check *Data Completeness Not Met*.

14. Check *Data Completeness Not Met*:

- If *Data Completeness Not Met*, the Quality Data Code or equivalent was not submitted. 10 patients have been subtracted from the Data Completeness Numerator in Sample Calculation.

### **Sample Calculations:**

Data Completeness equals Performance Met (a equals 40 patients) plus Performance Not Met (c equals 30 patients) divided by Eligible Population/Denominator (d equals 80 patients). All equals 70 patients divided by 80 patients. All equals 87.50 percent.

Performance Rate equals Performance Met (a equals 40 patients) divided by Data Completeness Numerator (70 patients). All equals 40 patients divided by 70 patients. All equals 57.14 percent.

\*See the posted measure specification for specific coding and instructions to submit this measure.

NOTE: Submission Frequency: Patient-Process

The measure diagrams were developed by CMS as a supplemental resource to be used in conjunction with the measure specifications. They should not be used alone or as a substitution for the measure specification.